The latest news about Samsung Bioepis
INCHEON, Korea – November 10, 2020 – Samsung Bioepis Co., Ltd. today announced the initiation of Phase 1 clinical trial for SB16, the company's proposed biosimilar referencing Prolia® (denosumab). The Phase 1 clinical trial for SB16 (denosumab) is a randomized, double-blind, three-arm, parallel group, single-dose study to compare the pharmacokinetics, pharmacodynamics, safety, tolerability, and immunogenicity between SB16 and Prolia® in healthy male volunteers. For more information, please visit clinicaltrials.gov (NCT04621318).
# # #
Anna Nayun Kim: +82-31-8061-1604, firstname.lastname@example.org